Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2008

View Archived Issues

ProMetic BioSciences products show potential in pancreatic, prostate cancer

Merrimack Pharmaceuticals describes activity of anti-ErbB3 monoclonal antibody MM-121

Jerini presents preclinical and clinical data for JSM-6427 in AMD and other ocular conditions

Charlesson reports on novel small molecules as potential treatments for retinal diseases

Novel anti-CD19 antibody shows preclinical activity against lymphoma and leukemia

Oxytocin receptor agonist has anxiolytic-like effects in rodent models

Recent Wyeth patent reports novel agents for acute coronary syndrome

New agents for treating respiratory disorders disclosed in recent patent literature

NCI awards AlphaMed USD 750,000 grant for targeted melanoma therapy

Sernova concludes successful pre-IND meeting with FDA for Sertolin in diabetes

GenVec receives SBIR grant of USD 600,000 for respiratory syncytial virus vaccine

Opko acquires Vidus Ocular

FDA accepts Osteologix's IND application for NB-S101 for osteoporosis

Orexigen completes enrollment in NB-303 and NB-304 phase III clinical trials for Contrave

Memantine reduces hyperactivity in a rat mania model

Recent Japanese patent describes new treatment options for gout

Acucela files IND with the FDA to conduct phase I study for ACU-02

AstraZeneca submits sNDA for Seroquel XR for GAD

BMP receives SFDA acceptance for Enablex clinical trial

FDA Advisory Committee votes in favor of approval of fospropofol disodium

KeyNeurotek's phase I KN38-7271 study meets all endpoints

Vion initiates investigator-sponsored phase I/II Cloretazine trial

FDA approves Abilify for add-on treatment to lithium or valproate in bipolar I

Takeda successfully completes tender offer for Millennium

Taisho initiates phase I clinical trial of psychiatric drug candidate under partnership with Arena

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...